By
Dr Ying K. Tam,
Sean Semple,
Dr Chris Barbosa,
Rob Leone and
Dr Paolo Lin2025-10-08T08:00:00
CRISPR therapies depend on delivery and lipid nanoparticles are emerging as a more flexible and scalable option than viral vectors.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-06-19T08:26:00Z
2026-06-17T12:40:00Z
2026-06-17T09:14:00Z
2023-02-16T14:53:10
Sponsored by Cell Signaling Technology
2023-01-16T10:21:42
Sponsored by Sartorius Incucyte® Live-Cell Analysis System
2023-12-11T10:49:07
Sponsored by Leica Microsystems
2023-02-13T11:57:11
Sponsored by Agilent
2025-06-02T10:00:00
Contributor Professor Stefan Trapp, By Drug Target Review
Site powered by Webvision Cloud